625 research outputs found
The Multiwavelength Survey By Yale-Chile (MUSYC) Wide K-Band Imaging, Photometric Catalogs, Clustering, And Physical Properties Of Galaxies At Z Similar To 2
We present K-band imaging of two similar to 30' x 30' fields covered by the Multiwavelength Survey by Yale-Chile (MUSYC) Wide NIR Survey. The SDSS 1030+05 and Cast 1255 fields were imaged with the Infrared Side Port Imager (ISPI) on the 4 m Blanco telescope at the Cerro Tololo Inter-American Observatory (CTIO) to a 5 sigma point-source limiting depth of K similar to 20 (Vega). Combining these data with the MUSYC optical UBVRIz imaging, we created multiband K-selected source catalogs for both fields. These catalogs, together with the MUSYC K-band catalog of the Extended Chandra Deep Field South (ECDF-S) field, were used to select K 20 BzK galaxies over an area of 0.71 deg(2). This is the largest area ever surveyed for BzK galaxies. We present number counts, redshift distributions, and stellar masses for our sample of 3261 BzK galaxies (2502 star-forming [sBzK] and 759 passively evolving [pBzK]), as well as reddening and star formation rate estimates for the star-forming BzK systems. We also present two-point angular correlation functions and spatial correlation lengths for both sBzK and pBzK galaxies and show that previous estimates of the correlation function of these galaxies were affected by cosmic variance due to the small areas surveyed. We have measured correlation lengths r(0) of 8.89 +/- 2.03 and 10.82 +/- 1.72 Mpc for sBzK and pBzK galaxies, respectively. This is the first reported measurement of the spatial correlation function of passive BzK galaxies. In the Lambda CDM scenario of galaxy formation, these correlation lengths at z similar to 2 translate into minimum masses of similar to 4 x 10(12) and similar to 9 x 10(12) M(circle dot) for the dark matter halos hosting sBzK and pBzK galaxies, respectively. The clustering properties of the galaxies in our sample are consistent with their being the descendants of bright Lyman break galaxies at z similar to 3, and the progenitors of present-day > 1L* galaxies.Astronom
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
SARS-CoV-2; Non-Hodgkin lymphoma; Targeted drugsSARS-CoV-2; Linfoma no Hodgkin; Medicamentos dirigidosSARS-CoV-2; Limfoma no Hodgkin; Medicaments dirigitsPatients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223)
Novel Methodology for the Detection of Enveloped Viruses
Presented at Viruses 2020âNovel Concepts in Virology, Barcelona, Spain, 5â7 February 2020 (abstract)Viral infections in humans cause a huge burden in worldwide healthcare that has increased due to the emergence of new pathogenic viruses, such as in the recent Ebola virus (EBOV) outbreaks. Viral particles in body fluids are often at very low levels, making diagnosis difficult. In order to address this problem, we have developed a new detection platform to isolate and detect different enveloped viruses. We have recently identified that sialic acid-binding Igâlike lectin 1 (Siglec-1/CD169) is one cellular receptor used by EBOV and HIV-1 to enter myeloid cells, key target cells for infection and pathogenesis. For viral uptake, the V-set domain of this myeloid cell receptor recognizes the gangliosides of viral membranes that were dragged during viral budding from the plasma membrane of infected cells. We took advantage of this specific interaction between Siglecâ1 and viral gangliosides to develop a new detection methodology. We have generated a recombinant protein that contains the V-set domain of Siglec-1 fused to the human IgG Fc domain for anchoring in latex beads. These coated beads allow the isolation of viral particles and their measurement by flow cytometry. We have tested its efficacy to detect HIV-1 and EBOV and its specificity by using anti-Siglecâ1 antibodies that prevent the interaction and serve as a negative control. To test the capacity of our method, we used synthetic liposomes to assess the effect of ganglioside concentration in membranes as well as the size of viral particles. This methodology would facilitate the diagnosis of infections by concentrating viral particles in a fast and direct method. At a time when global human mobility facilitates the dissemination of infectious agents, our approach represents a rapid and effective method to maximize the identification of both known and emerging enveloped viruses as part of public health viral surveillance strategies
Very early Guillain-Barré syndrome: A clinical-electrophysiological and ultrasonographic study
Objectives: Using recent optimized electrodiagnostic criteria sets, we primarily aimed at verifying the accuracy of the initial electrophysiological test in very early Guillain-Barré syndrome (VEGBS), ?4 days of onset, compared with the results of serial electrophysiology. Our secondary objective was to correlate early electrophysiological results with sonographic nerve changes.
Methods: This is a retrospective study based on consecutive VEGBS patients admitted to the hospital. Each patient had serial nerve conduction studies (NCS) in at least 4 nerves. Initial NCS were done within 4 days after onset, and serial ones from the second week onwards. Electrophysiological recordings of each case were re-evaluated, GBS subtype being established accordingly. Nerve ultrasonography was almost always performed within 2 weeks after onset.
Results: Fifteen adult VEGBS patients were identified with a mean age of 57.8 years. At first NCS, VEGBS sub-typing was only possible in 3 (20%) cases that showed an axonal pattern, the remaining patterns being mixed (combining axonal and demyelinating features) in 6 (40%), equivocal in 5 (33.3%), and normal in 1 (6.7%). Upon serial NCS, 7 (46.7%) cases were categorized as acute demyelinating polyneuropathy, 7 (46.7%) as axonal GBS, and 1 (6.6%) as unclassified syndrome. Antiganglioside reactivity was detected in 5 out of the 7 axonal cases. Nerve US showed that lesions mainly involved the ventral rami of scanned cervical nerves.
Conclusions: Serial electrophysiological evaluation is necessary for accurate VEGBS subtype classification. Ultrasonography helps delineate the topography of nerve changes.
Significance: We provide new VEGBS pathophysiological insights into nerve conduction alterations within the first 4 days of the clinical course.Acknowledgement: This paper was supported by IDIVAL (ID APG/11) and CIBERNED. The authors are most grateful to Mrs Marta de la Fuente for secretarial assistance
Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease
Objective: To assess the value of baseline clinical and imaging biomarkers in a cohort of asymptomatic
LRRK2 G2019S carriers for predicting conversion to Parkinson disease (PD) at 4 years.
Methods: Thirty-two asymptomatic carriers of LRRK2 G2019S mutation underwent baseline and
4-year evaluation including clinical examination (Unified Parkinson?s Disease Rating Scale, part III,
olfaction University of Pennsylvania Smell Identification Test [UPSIT]) and dopamine transporter
(DaT) SPECT (123I-ioflupane). Visual and semiquantitative analysis of images was performed. The
specific striatal binding ratio was calculated (striatal region of interest [ROI] 2 occipital ROI/
occipital ROI).
Results: Three carriers, asymptomatic at baseline, had converted to PD at 4-year evaluation.
Twenty-three participants were fully evaluated. PD converters had lower striatal DaT binding
at baseline than nonconverters (p 50.002). A baseline scan with a ratio of bilateral striatal uptake
below 1 predicted conversion to PD within the 4-year period with high sensitivity and specificity
(area under the curve 1; p 5 0.006). The slope of DaT binding decline between the 2 scans was
similar in PD converters and nonconverters. Age-adjusted UPSIT score at baseline and at 4 years
was similar in both groups.
Conclusions: Semiquantitative DaT-SPECT could be used to predict early conversion to PD in
asymptomatic carriers of the LRRK2 G2019S mutation. Rate of conversion to PD at 4 years in
this cohort aged ;64 years was 12%. The slope of DaT binding decline on DaT-SPECT imaging
seems to be similar across different stages of the premotor perio
The Multiwavelength Survey by Yale-Chile (MUSYC): Deep Near-Infrared Imaging and the Selection of Distant Galaxies
We present deep near-infrared JHK imaging of four 10'x10' fields. The
observations were carried out as part of the Multiwavelength Survey by
Yale-Chile (MUSYC) with ISPI on the CTIO 4m telescope. The typical point source
limiting depths are J~22.5, H~21.5, and K~21 (5sigma; Vega). The effective
seeing in the final images is ~1.0". We combine these data with MUSYC UBVRIz
imaging to create K-selected catalogs that are unique for their uniform size,
depth, filter coverage, and image quality. We investigate the rest-frame
optical colors and photometric redshifts of galaxies that are selected using
common color selection techniques, including distant red galaxies (DRGs),
star-forming and passive BzKs, and the rest-frame UV-selected BM, BX, and Lyman
break galaxies (LBGs). These techniques are effective at isolating large
samples of high redshift galaxies, but none provide complete or uniform samples
across the targeted redshift ranges. The DRG and BM/BX/LBG criteria identify
populations of red and blue galaxies, respectively, as they were designed to
do. The star-forming BzKs have a very wide redshift distribution, a wide range
of colors, and may include galaxies with very low specific star formation
rates. In comparison, the passive BzKs are fewer in number, have a different
distribution of K magnitudes, and have a somewhat different redshift
distribution. By combining these color selection criteria, it appears possible
to define a reasonably complete sample of galaxies to our flux limit over
specific redshift ranges. However, the redshift dependence of both the
completeness and sampled range of rest-frame colors poses an ultimate limit to
the usefulness of these techniques.Comment: 17 pages in emulateapj style, 13 figures. Submitted to the
Astronomical Journal. Data will be made available upon publicatio
The Atacama Cosmology Telescope: the stellar content of galaxy clusters selected using the Sunyaev-Zel'dovich effect
We present a first measurement of the stellar mass component of galaxy
clusters selected via the Sunyaev-Zel'dovich (SZ) effect, using 3.6 um and 4.5
um photometry from the Spitzer Space Telescope. Our sample consists of 14
clusters detected by the Atacama Cosmology Telescope (ACT), which span the
redshift range 0.27 < z < 1.07 (median z = 0.50), and have dynamical mass
measurements, accurate to about 30 per cent, with median M500 = 6.9 x 10^{14}
MSun. We measure the 3.6 um and 4.5 um galaxy luminosity functions, finding the
characteristic magnitude (m*) and faint-end slope (alpha) to be similar to
those for IR-selected cluster samples. We perform the first measurements of the
scaling of SZ-observables (Y500 and y0) with both brightest cluster galaxy
(BCG) stellar mass and total cluster stellar mass (M500star). We find a
significant correlation between BCG stellar mass and Y500 (E(z)^{-2/3} DA^2
Y500 ~ M*^{1.2 +/- 0.6}), although we are not able to obtain a strong
constraint on the slope of the relation due to the small sample size.
Additionally, we obtain E(z)^{-2/3} DA^2 Y500 ~ M500star^{1.0 +/- 0.6} for the
scaling with total stellar mass. The mass fraction in stars spans the range
0.006-0.034, with the second ranked cluster in terms of dynamical mass (ACT-CL
J0237-4939) having an unusually low total stellar mass and the lowest stellar
mass fraction. For the five clusters with gas mass measurements available in
the literature, we see no evidence for a shortfall of baryons relative to the
cosmic mean value.Comment: Accepted for publication in MNRAS; 12 pages, 10 figure
The Atacama Cosmology Telescope: Sunyaev-Zel'dovich Selected Galaxy Clusters at 148 GHz from Three Seasons of Data
[Abridged] We present a catalog of 68 galaxy clusters, of which 19 are new
discoveries, detected via the Sunyaev-Zel'dovich effect (SZ) at 148 GHz in the
Atacama Cosmology Telescope (ACT) survey of 504 square degrees on the celestial
equator. A subsample of 48 clusters within the 270 square degree region
overlapping SDSS Stripe 82 is estimated to be 90% complete for M_500c > 4.5e14
Msun and 0.15 < z < 0.8. While matched filters are used to detect the clusters,
the sample is studied further through a "Profile Based Amplitude Analysis"
using a single filter at a fixed \theta_500 = 5.9' angular scale. This new
approach takes advantage of the "Universal Pressure Profile" (UPP) to fix the
relationship between the cluster characteristic size (R_500) and the integrated
Compton parameter (Y_500). The UPP scalings are found to be nearly identical to
an adiabatic model, while a model incorporating non-thermal pressure better
matches dynamical mass measurements and masses from the South Pole Telescope. A
high signal to noise ratio subsample of 15 ACT clusters is used to obtain
cosmological constraints. We first confirm that constraints from SZ data are
limited by uncertainty in the scaling relation parameters rather than sample
size or measurement uncertainty. We next add in seven clusters from the ACT
Southern survey, including their dynamical mass measurements based on galaxy
velocity dispersions. In combination with WMAP7 these data simultaneously
constrain the scaling relation and cosmological parameters, yielding \sigma_8 =
0.829 \pm 0.024 and \Omega_m = 0.292 \pm 0.025. The results include
marginalization over a 15% bias in dynamical mass relative to the true halo
mass. In an extension to LCDM that incorporates non-zero neutrino mass density,
we combine our data with WMAP7+BAO+Hubble constant measurements to constrain
\Sigma m_\nu < 0.29 eV (95% C. L.).Comment: 32 pages, 21 figures To appear in J. Cosmology and Astroparticle
Physic
No association of CDK5 genetic variants with Alzheimer's disease risk
<p>Abstract</p> <p>Background</p> <p>As cyclin-dependent kinase 5 (CDK5) has been implicated in the abnormal hyperphosphorylation of tau in Alzheimer's disease (AD) brain, and the development of neurofibrillary tangles, we examined the contribution of this gene to the susceptibility for AD.</p> <p>Methods</p> <p>We examined genetic variations of CDK5 by genotyping haplotype tagging SNPs (htSNPs) (rs9278, rs2069459, rs891507, rs2069454, rs1549759 and rs2069442) in a group of 408 Spanish AD cases and 444 controls.</p> <p>Results</p> <p>There were no differences in the genotypic, allelic or haplotypic distributions between cases and controls in the overall analysis or after stratification by APOE Δ4 allele.</p> <p>Conclusion</p> <p>Our negative findings in the Spanish population argue against the hypothesis that CDK5 genetic variations are causally related to AD risk. Still, additional studies using different sets of patients and control subjects deserve further attention, since supporting evidence for association between CDK5 gene and AD risk in the Dutch population exists.</p
Falls predict acute hospitalization in Parkinson's disease
Background: There is a need for identifying risk factors for hospitalization in Parkinson's disease (PD) and also interventions to reduce acute hospital admission.
Objective: To analyze the frequency, causes, and predictors of acute hospitalization (AH) in PD patients from a Spanish cohort.
Methods: PD patients recruited from 35 centers of Spain from the COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015) cohort from January 2016 to November 2017, were included in the study. In order to identify predictors of AH, Kaplan-Meier estimates of factors considered as potential predictors were obtained and Cox regression performed on time to hospital encounter 1-year after the baseline visit.
Results: Thirty-five out of 605 (5.8%) PD patients (62.5±8.9 years old; 59.8% males) presented an AH during the 1-year follow-up after the baseline visit. Traumatic falls represented the most frequent cause of admission, being 23.7% of all acute hospitalizations. To suffer from motor fluctuations (HR [hazard ratio] 2.461; 95% CI, 1.065-5.678; p = 0.035), a very severe non-motor symptoms burden (HR [hazard ratio] 2.828; 95% CI, 1.319-6.063; p = 0.008), falls (HR 3.966; 95% CI 1.757-8.470; p = 0.001), and dysphagia (HR 2.356; 95% CI 1.124-4.941; p = 0.023) was associated with AH after adjustment to age, gender, disease duration, levodopa equivalent daily dose, total number of non-antiparkinsonian drugs, and UPDRS-IIIOFF. Of the previous variables, only falls (HR 2.998; 95% CI 1.080-8.322; p = 0.035) was an independent predictor of AH.
Conclusion: Falls is an independent predictor of AH in PD patients
- âŠ